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areas of low shear stress showed enhanced TGF-b-signaling 
activation and increased expression of the mesenchymal marker 
a-smooth muscle actin (aSMA).
These results suggest that the lack of cilia primes the endo thelial 
cells for shear-induced activation of TGF-b signaling and EndoMT. 
Juan Oliver
Urinary NGAL is a useful  
clinical biomarker of HIV-
associated nephropathy
Sola-Del Valle et al., Nephrol Dial Transplant advance online publication, 9 May 
2011, doi:10.1093/ndt/gfr258
The treatment of patients with HIV infection and kidney disease 
is greatly influenced by whether they have HIV-associated neph-
ropathy (HIVAN) or another glomerular disease, including his-
topathologies that could be related to HIV, such as membranous 
nephropathy, or complications of other comorbidities, such as dia-
betes mellitus or hypertension. Without kidney biopsy, the type of 
kidney disease an individual has is difficult to discern.1 Sola-Del 
Valle et al. examined urinary biomarkers to assess their ability to 
predict histology in patients with HIV and kidney disease who 
had undergone renal biopsy. Twenty-five patients were included, 
18 of whom had HIVAN and seven of whom had other glomeru-
lar lesions. Human recombinant neutrophil gelatinase-associ-
ated lipocalin (NGAL) protein, liver fatty acid-binding protein 
(L-FABP), and N-acetyl-b-d-glucosaminidase (NAG) were meas-
ured in stored urine specimens collected from each patient. Simi-
lar measurements were made for control subjects. Urinary NGAL 
levels were fourfold higher in people with HIVAN than in those 
with other diseases. Evaluation of various cutoffs for a dichotomous 
threshold to assess the likelihood of HIVAN over other glomerular 
diseases indicated that the threshold of 121.5 had a 94% sensitiv-
ity and a 71% specificity for the diagnosis of HIVAN. Similar but 
attenuated differences were seen in levels of FABP between patients 
with HIVAN and those with kidney diseases other than HIVAN. 
No differences were seen in urinary NAG levels. Other urinary 
biomarkers were measured, including FABP and NAG. NGAL had 
the highest area under the receiver operating characteristic curve 
(AUC). In receiver operating characteristic analysis, the AUC for 
NGAL was 0.88, compared with 0.80 and 0.61 for FABP and NAG, 
respectively. Values of NGAL and FABP were qualitatively lower 
but similar to those in patients with kidney diseases other than 
HIVAN among the HIV-negative control group.
This study suggests that urinary NGAL may have utility in 
predicting the likelihood of histological outcomes for patients 
with HIV and kidney disease. If further validated, this finding 
could have tremendous clinical significance and potentially 
support the earlier initiative of highly active antiretroviral 
therapy in this population.
Lynda Szczech
1Kidney Int 2004; 66: 1145–1152.
Lack of primary cilia facilitates 
shear-induced endothelial-to-
mesenchymal transition
Egorova et al., Circ Res 2011; 108: 1093–1101; doi:10.1161/
CIRCRESAHA.110.231860
A current controversy in renal research is the origin of the 
fibroblasts and myofibroblasts (fibroblasts that express a-smooth 
muscle actin) that characterize many progressive renal diseases. 
It is possible that these cells are generated by proliferating endog-
enous fibroblasts, derived from resident mesenchymal stem cells 
or pericytes, or derived from epithelial or endothelial cells by the 
process of epithelial- or endothelial-to-mesenchymal transition 
(EMT or EndoMT, respectively). Endothelial cells are exposed 
to hemodynamic forces of which shear stress represents the 
drag force on the endothelium exerted by blood flow. The cells 
respond to changes in flow by mechanosensing and mechan-
otransduction mechanisms in which cilia are believed to play an 
important role. Primary cilia can sense shear stresses, and it is 
believed that they function as flow sensors in epithelia, endothe-
lium, and other cell types. In endothelium, fluid flow changes 
cause ciliary deformation, leading to a polycystin-mediated 
intracellular Ca2+ transient within seconds. Furthermore, the 
cilium is believed to amplify the cytoskeletal strain, resulting 
in a prolonged effect on gene expression of shear-responsive 
genes, including Krüppel-like factor 2, which further coordi-
nates a major part of the phenotypic response of endothelial cells 
to shear forces. In a recent study, Egorova et al. used transgenic 
embryonic endothelial cells from the Tg737orpk/orpk mouse, 
which lacks primary cilia, to examine the role of this organelle 
in the cells’ response to fluid shear stress. In vitro, they found 
that shear stress triggered EndoMT in non-ciliated endothelial 
cells, but not in ciliated cells (Figure). Interestingly, the ciliation 
phenotype of the cells did not affect their capacity to undergo 
EndoMT induced by transforming growth factor-b (TGF-b) 
ligand. To assess the consequences of the lack of endothelial 
cilia in vivo, the authors examined the hearts of wild-type and 
Tg737orpk/orpk mice. They found that endothelial cells lining 
Shear stress-induced EndoMT in non-ciliated endothelial cells. CD31 and 
aSMA staining of wild-type (WT) and non-ciliated (Tg737orpk/orpk) endothelial 
cells under static conditions and after exposure to 0.5 Pa shear stress.
Eg
or
ov
a 
et
 a
l./
Ci
rc
 R
es
130   Kidney International (2011) 80
journal  c lub
Common variation in the gene 
of glypican-5 is associated with 
acquired nephrotic syndrome
Okamoto et al., Nat Genet 2011; 4: 459–463; doi:10.1038/ng.792
Work done over the past few decades has shown that mutations 
of a variety of podocyte-related genes can cause nephrotic pro-
teinuria. Since primary causes of acquired nephrotic syndrome 
are many, it is assumed that the disease is caused by numerous 
genetic and environmental factors. Indeed, recent genome-wide 
association studies have identified a region containing MYH9 and 
APOL1 as being associated with susceptibility to focal segmental 
glomerulosclerosis. To identify additional susceptibility genes that 
might contribute to nephrotic proteinuria in various glomerular 
and systemic diseases, Okamoto et al. conducted a genome-wide 
association study using individuals with biopsy-proven neph-
rotic syndrome. They first genotyped 268,068 single-nucleotide 
polymorphisms (SNPs) in 195 patients with nephrotic syndrome 
and 1546 controls but could not find SNP that achieved genome-
wide significance. Next, they selected 10,299 SNPs showing either 
an allelic or a genotypic P value less than 0.05 and genotyped 
them in an independent sample set comprising 231 patients with 
nephrotic syndrome and 1548 controls, from which they selected 
10 SNPs that had a significant P value. They finally genotyped 
a third independent panel of 431 patients with nephrotic syn-
drome and 3371 controls. With this approach, they identified an 
association with rs16946160 in intron 2 of GPC5, which encodes 
glypican-5 (GPC5), a member of the cell-surface heparan sulfate 
proteoglycan family. To explore the potential role of glypican-5 
in proteinuria, they next conducted a variety of studies and found 
that GPC5 expression was prominent in the glomerulus and that 
it localized in podocytes (Figure) and renal capillary endothelial 
cells. The members of the glypican family bind a multitude of 
growth factors, including fibroblast growth factor 2 (FGF2), and 
glypicans are necessary for FGF2 signal transduction. In experi-
ments with control and podocyte-specific Gpc5 knock-down 
mice, the authors found that single injection of either puromycin 
aminonucleoside (PAN) or FGF2 did not induce nephrotic pro-
teinuria, but when they injected both PAN and FGF2, massive 
albuminuria occurred in control mice and only mild albuminuria 
in the podocyte-specific Gpc5 knock-down mice. In sum, genome-
wide association and functional studies have identified GPC5 as a 
new susceptibility gene for nephrotic syndrome that contributes 
to podocyte injury in glomerular diseases of different etiologies. 
Finally, the study suggests that suppression of Gpc5 might be a 
therapeutic target in nephrotic syndrome.
Juan Oliver
Suppressed monocyte recruitment 
drives macrophage removal from 
atherosclerotic plaques of Apoe–/– 
mice during disease regression
Potteaux et al., J Clin Invest 2011; 121: 2025–2036; doi:10.1172/JCI43802
Atherosclerosis is a chronic inflammatory disease that develops 
silently over decades, progressively evolving from fatty streaks 
characterized mainly by monocyte-derived cells filled with cho-
lesterol esters to advanced plaques with more complex cellular 
composition, lipid pools filled with necrotic debris, and calcified 
material. Experimental models of atherosclerosis suggest that 
recruitment of monocytes into plaques drives the progression 
of this chronic inflammatory condition. Cholesterol-lowering 
therapy leads to plaque stabilization or regression in human 
atherosclerosis, characterized by reduced macrophage con-
tent. However, the mechanisms that underlie this reduction are 
incompletely understood. Mice lacking the gene Apoe (Apoe–/– 
mice) have high levels of cholesterol and spontaneously develop 
atherosclerotic lesions. Potteaux et al. treated Apoe–/– mice with 
apoE-encoding adenoviral vectors that induce plaque regression 
and investigated whether macrophage removal from plaques 
during this regression resulted from quantitative alterations in 
the ability of monocytes to either enter or exit plaques. Within 2 
days after apoE complementation, plasma cholesterol was nor-
malized to wild-type levels, and high-density lipoprotein levels 
were increased fourfold. Oil red O staining and quantitative 
mass spectroscopy revealed that esterified cholesterol content 
was markedly reduced. Plaque macrophage content decreased 
gradually and was 72% lower than baseline 4 weeks after apoE 
complementation. Importantly, this reduction in macrophages 
did not involve migratory egress from plaques or CCR7, a medi-
ator of leukocyte emigration. Instead, marked suppression of 
monocyte recruitment coupled with a stable rate of apoptosis 
accounted for the loss of plaque macrophages. These data sug-
gest that therapies to inhibit monocyte recruitment to plaques 
may constitute a more viable strategy to reduce plaque macro-
phage burden than attempts to promote migratory egress.
This study supports the idea that interfering with monocyte 
recruitment into plaques may be therapeutically beneficial, though 
it is also clear that such an approach should be carried out as ancil-
lary therapy with aggressive lipid lowering in order to maintain and 
reinforce reductions in monocyte recruitment.
Marc De Broe Human kidney shows staining for GPC5 (green) and nephrin (blue).
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